840034C

16:0–18:1 PS (POPS)

Avanti Research^™ - A Croda Brand

• Synonym(e): 1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serin (Natriumsalz); POPS; PS(16:0/18:1(9Z)); 110669
• Empirische Formel (Hill-System): C₄₀H₇₅NO₁₀PNa
• CAS-Nummer: 321863-21-2
• Molekulargewicht: 783.99
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Beschreibung: 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (sodium salt), chloroform
• Assay: >99% (TLC)
• Form: liquid
• Verpackung: pkg of 1 × 1 mL (840034C-10mg); pkg of 1 × 2.5 mL (840034C-25mg); pkg of 2 × 4 mL (840034C-200mg); pkg of 5 × 4 mL (840034C-500mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand
• Konzentration: 10 mg/mL (840034C-10mg); 10 mg/mL (840034C-25mg); 25 mg/mL (840034C-200mg); 25 mg/mL (840034C-500mg)
• Lipid-Typ: cardiolipins; phospholipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: [H][C@@](COP([O-])(OC[C@](C([O-])=O)([H])[NH3+])=O)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O.[Na+]

Beschreibung

Verpackung

Versiegelte 5-ml-Klarglas-Ampulle (840034C-10mg)

Versiegelte 5-ml-Klarglas-Ampulle (840034C-200mg)

Versiegelte 5-ml-Klarglas-Ampulle (840034C-25mg)

Versiegelte 5-ml-Klarglas-Ampulle (840034C-500mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Piktogramme: GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H302,H315,H319,H331,H336,H351,H361d,H372,H412
• P-Sätze: P201 - P273 - P301 + P312 + P330 - P302 + P352 - P304 + P340 + P311 - P308 + P313
• Gefahreneinstufungen: Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3
• Zielorgane: Central nervous system, Liver,Kidney
• Lagerklassenschlüssel: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable